![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: Synovial sarcoma (SS) is an aggressive mesenchymal malignancy spanning the pediatric and adult age groups. The role of chemotherapy in this tumor is still controversial, and different strategies have been adopted in the past for pediatric and adult groups.
Areas covered: This paper describes the main published data on SS, focusing particularly on the efficacy of chemotherapy. Clinical approaches have tended to converge towards a common strategy, and chemotherapy is generally recommended nowadays based on patients’ risk stratification.
Expert opinion: New effective molecular targeting agents are needed to improve the outcome of high-risk patients with SS (especially metastasizing and relapsing cases). But until such novel alternatives have been included in clinical trials, it is essential that clinicians learn how to make better use of currently available drugs, that is, full-dose ifosfamide-doxorubicin chemotherapy. The selection of patients who should receive chemotherapy might be improved by recent findings on somatic genomic abnormalities.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Notes
This box summarizes key points contained in the article.